b 927 5 (Trexall 5 mg)
Generic Name: methotrexate
Pill imprint b 927 5 has been identified as Trexall 5 mg.
Trexall is used in the treatment of rheumatoid arthritis; psoriasis; psoriatic arthritis; breast cancer; osteosarcoma (and more), and belongs to the drug classes antimetabolites, antipsoriatics, antirheumatics, other immunosuppressants. Not for use in pregnancy. Trexall 5 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for b 927 5 (Trexall 5 mg)
- Generic Name:
- methotrexate
- Imprint:
-
b
927 5 - Strength:
- 5 mg
- Color:
- Green
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Drug Class:
- Antimetabolites
Antipsoriatics
Antirheumatics
Other immunosuppressants - Pregnancy Category:
- X - Not for use in pregnancy
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Barr Laboratories, Inc.
More resources
Trexall is associated with the treatment of:
- Acute Lymphoblastic Leukemia
- Acute Lymphocytic Leukemia
- Acute Nonlymphocytic Leukemia
- Bladder Cancer
- Brain Tumor
- Breast Cancer
- Bullous Pemphigoid
- Cervical Cancer
- Choriocarcinoma
- Cogan's Syndrome
- Colorectal Cancer
- Dermatomyositis
- Ectopic Pregnancy
- Eczema
- Esophageal Carcinoma
- Gastric Cancer
- Graft-versus-host disease
- Head and Neck Cancer
- Hodgkin's Lymphoma
- Lymphoma
- Meningeal Leukemia
- Mycosis Fungoides
- Neoplastic Diseases
- Non-Hodgkin's Lymphoma
- Non-Small Cell Lung Cancer
- Osteosarcoma
- Ovarian Cancer
- Pancreatic Cancer
- Pemphigoid
- Pemphigus
- Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Small Cell Lung Cancer
- Soft Tissue Sarcoma
- Solid Tumors
- Systemic Sclerosis
- Trophoblastic Disease
- Uveitis
Search by Imprint, Shape or Color
Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...

